Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy in advanced esophagogastric adenocarcinoma
2014-000127-24Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Feb 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carboplatin, docetaxel, capecitabine, epirubicin and oxaliplatin in gastroesophageal junction adenocarcinoma and esophagogastric junction cancer (2 arms), sponsored by Rigshospitalet. Primary endpoint: 1-year survival rate associated with CTX. Started Feb 2014; status: completed.
02
Drugs
carboplatindocetaxelcapecitabineepirubicinoxaliplatin
03
Conditions
gastroesophageal junction adenocarcinomaesophagogastric junction cancer
Beyond the preview
Go deeper on 2014-000127-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000127-24.